BPC-157 (Pentadecapeptide)

BPC-157 Studied Effects, Sorted by Evidence

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-234 cited sources

The short answer

Reported effects span gastrointestinal lesion and fistula models, tendon and ligament repair, vascular effects and more. Nearly all are rat models from one research group. Clinical development occurred as PL-14736 for inflammatory bowel disease, and a Phase 2 is recruiting.

Key facts

Gastrointestinal
Lesion and fistula models
Musculoskeletal
Tendon, ligament, muscle
Vascular
Angiogenesis, blood vessel effects
Clinical
PL-14736 for IBD; Phase 2 recruiting
Dominant model
Rat
Receptor
None identified

Sorted by how well established

Best supported: the gastrointestinal work, which is the oldest thread, the closest to the compound's proposed origin, and the one that reached clinical development as PL-14736. Then the musculoskeletal work, with two studies in the Journal of Orthopaedic Research and a human trial now testing it. Then the vascular findings, which may underlie the others. Least supported: the broader claims that follow from breadth rather than from any specific study.

The gastrointestinal thread

Lesion models and fistula healing recur throughout, and Sikirić and colleagues reported on fistula healing in Current Pharmaceutical Design in 2020. This is the thread that made it to human trials for inflammatory bowel disease, reported in Inflammopharmacology in 2006, which makes it the most developed line of evidence the compound has.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £16.95

The musculoskeletal thread

Krivic 2006 on Achilles detachment and Cerovecki 2010 on ligament healing, both in the Journal of Orthopaedic Research. This is the thread the current Phase 2 trial tests, in acute hamstring muscle strain, meaning a preclinical line is about to meet a randomised placebo-controlled human endpoint.

What is absent

A molecular target. Substantial independent replication outside the Zagreb group. And any reported clinical result: the Phase 1 record has not been updated and the Phase 2 has not completed. None of these absences refutes the preclinical findings; together they mark the boundary of what can be said.

How it compares within this library

BPC-157 has the most clinical development of any compound in these categories, and one of the weaker mechanistic pictures. DSIP has neither. GHK-Cu has better-defined chemistry and no clinical programme. TB-500 has a clearer molecular function and no trials. That combination of real clinical progress on an unmapped mechanism is unusual.

Frequently asked questions

What is BPC-157 best supported for?

The gastrointestinal work, which is the oldest thread and the one that reached clinical development as PL-14736 for inflammatory bowel disease.

Is there a clinical result?

No. The Phase 1 record has not been updated and the Phase 2 trial has not completed; primary completion is due February 2027.

How does it compare to the other compounds here?

It has the most clinical development and one of the weakest mechanistic pictures, which is an unusual combination.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More BPC-157 (Pentadecapeptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.